McKesson Corporation and Clayton Dubilier & Rice agreed Tuesday to take Option Care Health private in a $5.8 billion transaction, removing the largest independent provider of home and alternate site infusion services from public markets. The deal pairs a Fortune 10 pharmaceutical distributor with a buyout shop known for operational turnarounds in healthcare services.
Option Care operates over 100 infusion pharmacies across the United States, serving roughly 200,000 patients annually with therapies ranging from immunoglobulins to biologics for chronic conditions. The company emerged from the 2019 merger of Option Care and BioScrip, itself a consolidation designed to achieve scale in a fragmented market where reimbursement pressure from commercial payers and Medicare Advantage plans has intensified. Revenue for the trailing twelve months stands near $4.7 billion, implying the buyers are paying roughly 1.23 times sales for a business with mid-single-digit EBITDA margins. McKesson already distributes specialty pharmaceuticals to infusion providers and has been expanding its capabilities in specialty distribution and patient services through investments in US Oncology and its specialty health division.
The move reflects two converging dynamics allocators tracking healthcare services should note. First, home infusion economics are bifurcating. High-acuity specialty drugs with robust reimbursement profiles—CAR-T therapies, monoclonals for rare diseases, gene therapies migrating to outpatient settings—offer margin expansion, while generic IV antibiotics and parenteral nutrition face margin compression as payers push unit costs down. Option Care's exposure tilts toward the former, but public market investors have punished the equity for lumpy quarterly results tied to payer contract renewals and prior authorization delays. Taking the business private allows McKesson and CD&R to restructure operations around the high-margin specialty book without quarterly earnings volatility. Second, McKesson gains vertical integration into the administration layer. The company already profits from distributing specialty drugs; owning the infusion site lets it capture the service margin and negotiate bundled contracts with health systems and payers seeking simplified vendor relationships. This is the distribution model McKesson has pursued in oncology through its practice-management joint ventures, now extended to infusion.
Operators and allocators should watch for three follow-on events. McKesson will likely announce the divestiture or wind-down of Option Care's lower-margin acute infusion contracts within six to nine months post-close, reallocating capital to specialty drug categories where the company has formulary relationships. CD&R has a pattern of installing operational partners to re-engineer cost structures; expect announcements around supply chain integration and site consolidation in Q1 2026. Finally, this transaction invites a broader question about specialty pharmacy consolidation. Walgreens, CVS Health, and a handful of private equity-backed regional players operate similar infusion platforms. If McKesson extracts the margin expansion it projects, those competitors face a choice: pair with a distributor themselves or risk losing share to an integrated competitor.
The deal is expected to close mid-2025, subject to regulatory clearance and shareholder approval. McKesson's specialty health division generated $39 billion in revenue last fiscal year; adding Option Care's $4.7 billion represents a 12% bump to that segment, but more importantly, it's the first time McKesson has acquired the administration endpoint in specialty care. The company has been public about wanting to own more of the patient services layer. This is how they get there.
The takeaway
McKesson and CD&R are paying 1.23x sales to control the administration layer in specialty infusion, signaling vertical integration in high-margin therapies.
Editorial & Disclosure Notice: This article was written with artificial intelligence from public sources and is published without individual human review. Artificial intelligence and other digital tools are also used for research, analysis, editing, formatting, and production. Errors, omissions, outdated information, or inaccuracies may occur. References to companies, brands, products, services, organizations, or individuals are for informational and editorial purposes and do not imply endorsement, sponsorship, affiliation, partnership, or approval unless expressly stated. All trademarks and other intellectual property remain the property of their respective owners. Opinions, analysis, estimates, and commentary are informational only and should not be construed as financial, investment, legal, tax, medical, procurement, or other professional advice. Information may be corrected, clarified, or updated after publication. Corrections or removal requests: jenny@pops4.com.
Want the 60-second program for your specific event?
Enter your event and email — we build it and send the branded proposal before lunch. No obligation.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.